viewRhinomed Ltd

Rhinomed’s strong growth and global product expansion reflects maturing business

Rhinomed Ltd (ASX:RNO) chief executive officer Michael Johnson speaks to Proactive Investors about the Melbourne-based tech company’s suite of consumer health products and its recent licencing deal with medical cannabis major Columbia Care.

“We’ve now had six consecutive quarters of growth – this quarter we expect to report our seventh consecutive quarter of growth,” Johnson says.

He continues, “we shipped 229,000 units over the financial year, we expect to significantly grow that over this financial year and that’s certainly funding the company, that’s driving us to what we hope will be breaking even within the next financial year.

“As we grow we can start to move away from reliance purely on equity to looking at more traditional ways of financing the company … which is really reflective of the fact that the business is maturing.”

Quick facts: Rhinomed Ltd

Price: 0.175 AUD

Market: ASX
Market Cap: $44.42 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Trump Vs Biden debate: Market reaction, corporate support and future predictions

Neil Wilson from Markets.com joins Proactive London's Katie Pilbeam following the U.S. President Donald Trump and Democratic rival Joe Biden debate on Thursday night. With 47 million Americans already voted - do the markets even care? Wilson says there was 'no killer blow' which would explain...

2 days, 5 hours ago

2 min read